model updat thought speak
compani second opinion
strong quarter guidanc rais set stage import
share move follow strong beat guidanc rais
acknowledg strength busi remain cautiou ahead
result rewind cardiovascular outcom trial trulic
publish last month believ chanc trulic
show cardiovascular superior trial see risk/reward
skew downsid data readout quarter howev
trulic along verzenio import new product beat
estim increas base case estim product
valuat rais target price respons
strong quarter maintain under-perform rate base
conserv view outcom rewind trial come
target price base dcf rel valuat
earn blue sky valuat grey sky valuat
sotp analysi suggest valuat
ep estim increas
pleas let us know would like updat compani model
risk primari risk rate target price includ
overli posit data rewind continu strong trulic uptak
despit increas competit commerci execut busi
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
price jul rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
trulic jardianc taltz galcanezumab olumi verzenio
lartruvo compar current base case assumpt also
model higher gross margin oper margin base
case assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale trulic
jardianc taltz galcanezumab olumi verzenio lartruvo
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
current conserv assum trulic yield similar data rewind trial
saw victoza leader base trulic estim assumpt
howev present sensit analysi possibl outcom rewind
impact dcf valu order posit neg
outcom perspect
trulic superior overal popul result
look substanti better victoza leader
though think unlik scenario would see trulic arm
power market tool combat ozemp weight loss profil grow market
share result could see stock
trulic statist superior reduc cv risk similar victoza
base case current model believ also current
built consensu believ outcom would result minor relief ralli
share
trulic numer benefici cv risk reach statist
signific patient subgroup prior cv diseas
look leader trial though victoza demonstr superior
much room error achiev statist signific upper ci
bound think
healthier popul rewind trial make difficult
establish superior studi whole longer trial time trulic
show benefit popul leader despit fewer
patient allow benefit approv label albeit restrict
prior cv diseas would expect stock weak
trulic show zero cv benefit hazard ratio near patient
scenario would like result rapid drop-off trulic market share
believ steep discount would necessari maintain place
formulari result could send stock weaker
trulic statist harm hazard ratio greater
year dcf
think highli unlik trial would like halt
dsmb rare event outcom would lead stock
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect around fy
summar compani answer question
embrac open access formulari exclusionari tactic
novo well said much
want continu polici
possibl azn could wildcard would tough sell
payer tri exclud lilli novo
estim trial complet realli chang
event driven tough pin exact end date studi
revenu growth half growth
increas co-pay card util cut growth bit
littl bit sale come psoriat arthriti psoriasi
enter rheumatologist offic
rheumatologist also tend conserv well
sanofi taken highli rebat medicaid segment
alreadi price cap
help lli segment mix price consider
one monotherapi indic
first quarter indic
soon tell launch go
strong result germani
sale eu half germani
said give sampl much
option get dose market
share much yet
on-going post-market commit fda includ long term
safeti studi ra patient still dose
fda ask stop studi on-going studi
certainli see path forward indic
sure
issu aimovig fill high demand address demand launch
auto-injector launch
everi confid readi demand
believ approach indic specialti standpoint
patient diagnos migrain annual
estim actual
believ new medicin class increas diagnosi rate
share repurchas program open-end
humalog time chang estim discount
ad growth us
jardianc time chang estim discount
alimta growth due ad use follow keytruda readout
charl martineau univers toronto figur part analysi
us million unless otherwis state
total compani
total compani
total compani ev
mix global biopharma compani
mix product distributor
us million unless otherwis state
sale
sale
figur cs comparison guidanc
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
sale
total incom expens
provis incom tax
us million unless otherwis state
us million unless otherwis state
galcanezumab migrain headach
compani mention price
